GlassScriptPhysician profile
Joseph John Drabick
NPI 1104875871
$53,280.20
in general payments reported to CMS, 2019-2025
23 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $9,830 · 2021: $7,190 · 2022: $16K · 2023: $349 · 2024: $244 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.06 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50,968.13 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $364.78 | 2019-2024 | Opdivo |
| Incyte Corporation | $257.00 | 2021-2023 | Monjuvi, Jakafi, Pemazyre |
| Seagen INC. | $249.98 | 2021-2023 | Adcetris |
| Tactile Systems Technology INC | $162.31 | 2021 | |
| Alexion Pharmaceuticals, INC. | $132.79 | 2022-2025 | Ultomiris |
| Daiichi Sankyo INC. | $122.85 | 2021-2025 | Datroway |
| Astrazeneca Pharmaceuticals LP | $122.22 | 2019 | |
| Springworks Therapeutics, INC. | $100.80 | 2024 | Ogsiveo |
| Eusa Pharma (US) LLC | $100.79 | 2019 | |
| Caris Mpi, INC. | $88.13 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $86.04 | 2019 | |
| Janssen Scientific Affairs, LLC | $85.01 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $83.89 | 2019 | |
| Myovant Sciences INC. | $75.60 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $74.79 | 2022 | |
| Puma Biotechnology, INC. | $74.55 | 2021 | |
| Paratek Pharmaceuticals, INC. | $69.19 | 2021 | |
| Servier Pharmaceuticals LLC | $23.63 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.70 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Drabick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.